Development and validation of a six-gene recurrence risk score assay for gastric cancer

Keun Wook Lee, Sung Sook Lee, Jun Eul Hwang, Hee Jin Jang, Hyun Sung Lee, Sang Cheul Oh, Sang Ho Lee, Bo Hwa Sohn, Sang Bae Kim, Jae Jun Shim, Woojin Jeong, Minse Cha, Jae Ho Cheong, Jae Yong Cho, Jae Yun Lim, Eun Sung Park, Sang Cheol Kim, Yoon Koo Kang, Sung Hoon Noh, Jaffer A. AjaniJu Seog Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: This study was aimed at developing and validating a quantitative multigene assay for predicting tumor recurrence after gastric cancer surgery. Experimental Design: Gene expression data were generated from tumor tissues of patients who underwent surgery for gastric cancer (n = 267, training cohort). Genes whose expression was significantly associated with activation of YAP1 (a frequently activated oncogene in gastrointestinal cancer), 5-year recurrence-free survival, and 5-year overall survival were first identified as candidates for prognostic genes (156 genes, P < 0.001). We developed the recurrence risk score (RRS) by using quantitative RT-PCR to identify genes whose expression levels were significantly associated with YAP1 activation and patient survival in the training cohort. Results: We based the RRS assay on 6 genes, IGFBP4, SFRP4, SPOCK1, SULF1, THBS, and GADD45B, whose expression levels were significantly associated with YAP1 activation and prognosis in the training cohort. The RRS assay was further validated in an independent cohort of 317 patients. In multivariate analysis, the RRS was an independent predictor of recurrence [HR, 1.6; 95% confidence interval (CI), 1.02-2.4; P = 0.03]. In patients with stage II disease, the RRS had an HR of 2.9 (95% CI, 1.1-7.9; P = 0.03) and was the only significant independent predictor of recurrence. Conclusions: The RRS assay was a valid predictor of recurrence in the two cohorts of patients with gastric cancer. Independent prospective studies to assess the clinical utility of this assay are warranted.

Original languageEnglish
Pages (from-to)6228-6235
Number of pages8
JournalClinical Cancer Research
Volume22
Issue number24
DOIs
Publication statusPublished - 2016 Dec 15

Fingerprint

Stomach Neoplasms
Recurrence
Genes
Gene Expression
Survival
Confidence Intervals
Gastrointestinal Neoplasms
Oncogenes
Neoplasms
Research Design
Multivariate Analysis
Prospective Studies
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Development and validation of a six-gene recurrence risk score assay for gastric cancer. / Lee, Keun Wook; Lee, Sung Sook; Hwang, Jun Eul; Jang, Hee Jin; Lee, Hyun Sung; Oh, Sang Cheul; Lee, Sang Ho; Sohn, Bo Hwa; Kim, Sang Bae; Shim, Jae Jun; Jeong, Woojin; Cha, Minse; Cheong, Jae Ho; Cho, Jae Yong; Lim, Jae Yun; Park, Eun Sung; Kim, Sang Cheol; Kang, Yoon Koo; Noh, Sung Hoon; Ajani, Jaffer A.; Lee, Ju Seog.

In: Clinical Cancer Research, Vol. 22, No. 24, 15.12.2016, p. 6228-6235.

Research output: Contribution to journalArticle

Lee, KW, Lee, SS, Hwang, JE, Jang, HJ, Lee, HS, Oh, SC, Lee, SH, Sohn, BH, Kim, SB, Shim, JJ, Jeong, W, Cha, M, Cheong, JH, Cho, JY, Lim, JY, Park, ES, Kim, SC, Kang, YK, Noh, SH, Ajani, JA & Lee, JS 2016, 'Development and validation of a six-gene recurrence risk score assay for gastric cancer', Clinical Cancer Research, vol. 22, no. 24, pp. 6228-6235. https://doi.org/10.1158/1078-0432.CCR-15-2468
Lee, Keun Wook ; Lee, Sung Sook ; Hwang, Jun Eul ; Jang, Hee Jin ; Lee, Hyun Sung ; Oh, Sang Cheul ; Lee, Sang Ho ; Sohn, Bo Hwa ; Kim, Sang Bae ; Shim, Jae Jun ; Jeong, Woojin ; Cha, Minse ; Cheong, Jae Ho ; Cho, Jae Yong ; Lim, Jae Yun ; Park, Eun Sung ; Kim, Sang Cheol ; Kang, Yoon Koo ; Noh, Sung Hoon ; Ajani, Jaffer A. ; Lee, Ju Seog. / Development and validation of a six-gene recurrence risk score assay for gastric cancer. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 24. pp. 6228-6235.
@article{9af94bd2bd0f48fcae64dcba4f0fad40,
title = "Development and validation of a six-gene recurrence risk score assay for gastric cancer",
abstract = "Purpose: This study was aimed at developing and validating a quantitative multigene assay for predicting tumor recurrence after gastric cancer surgery. Experimental Design: Gene expression data were generated from tumor tissues of patients who underwent surgery for gastric cancer (n = 267, training cohort). Genes whose expression was significantly associated with activation of YAP1 (a frequently activated oncogene in gastrointestinal cancer), 5-year recurrence-free survival, and 5-year overall survival were first identified as candidates for prognostic genes (156 genes, P < 0.001). We developed the recurrence risk score (RRS) by using quantitative RT-PCR to identify genes whose expression levels were significantly associated with YAP1 activation and patient survival in the training cohort. Results: We based the RRS assay on 6 genes, IGFBP4, SFRP4, SPOCK1, SULF1, THBS, and GADD45B, whose expression levels were significantly associated with YAP1 activation and prognosis in the training cohort. The RRS assay was further validated in an independent cohort of 317 patients. In multivariate analysis, the RRS was an independent predictor of recurrence [HR, 1.6; 95{\%} confidence interval (CI), 1.02-2.4; P = 0.03]. In patients with stage II disease, the RRS had an HR of 2.9 (95{\%} CI, 1.1-7.9; P = 0.03) and was the only significant independent predictor of recurrence. Conclusions: The RRS assay was a valid predictor of recurrence in the two cohorts of patients with gastric cancer. Independent prospective studies to assess the clinical utility of this assay are warranted.",
author = "Lee, {Keun Wook} and Lee, {Sung Sook} and Hwang, {Jun Eul} and Jang, {Hee Jin} and Lee, {Hyun Sung} and Oh, {Sang Cheul} and Lee, {Sang Ho} and Sohn, {Bo Hwa} and Kim, {Sang Bae} and Shim, {Jae Jun} and Woojin Jeong and Minse Cha and Cheong, {Jae Ho} and Cho, {Jae Yong} and Lim, {Jae Yun} and Park, {Eun Sung} and Kim, {Sang Cheol} and Kang, {Yoon Koo} and Noh, {Sung Hoon} and Ajani, {Jaffer A.} and Lee, {Ju Seog}",
year = "2016",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-15-2468",
language = "English",
volume = "22",
pages = "6228--6235",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Development and validation of a six-gene recurrence risk score assay for gastric cancer

AU - Lee, Keun Wook

AU - Lee, Sung Sook

AU - Hwang, Jun Eul

AU - Jang, Hee Jin

AU - Lee, Hyun Sung

AU - Oh, Sang Cheul

AU - Lee, Sang Ho

AU - Sohn, Bo Hwa

AU - Kim, Sang Bae

AU - Shim, Jae Jun

AU - Jeong, Woojin

AU - Cha, Minse

AU - Cheong, Jae Ho

AU - Cho, Jae Yong

AU - Lim, Jae Yun

AU - Park, Eun Sung

AU - Kim, Sang Cheol

AU - Kang, Yoon Koo

AU - Noh, Sung Hoon

AU - Ajani, Jaffer A.

AU - Lee, Ju Seog

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Purpose: This study was aimed at developing and validating a quantitative multigene assay for predicting tumor recurrence after gastric cancer surgery. Experimental Design: Gene expression data were generated from tumor tissues of patients who underwent surgery for gastric cancer (n = 267, training cohort). Genes whose expression was significantly associated with activation of YAP1 (a frequently activated oncogene in gastrointestinal cancer), 5-year recurrence-free survival, and 5-year overall survival were first identified as candidates for prognostic genes (156 genes, P < 0.001). We developed the recurrence risk score (RRS) by using quantitative RT-PCR to identify genes whose expression levels were significantly associated with YAP1 activation and patient survival in the training cohort. Results: We based the RRS assay on 6 genes, IGFBP4, SFRP4, SPOCK1, SULF1, THBS, and GADD45B, whose expression levels were significantly associated with YAP1 activation and prognosis in the training cohort. The RRS assay was further validated in an independent cohort of 317 patients. In multivariate analysis, the RRS was an independent predictor of recurrence [HR, 1.6; 95% confidence interval (CI), 1.02-2.4; P = 0.03]. In patients with stage II disease, the RRS had an HR of 2.9 (95% CI, 1.1-7.9; P = 0.03) and was the only significant independent predictor of recurrence. Conclusions: The RRS assay was a valid predictor of recurrence in the two cohorts of patients with gastric cancer. Independent prospective studies to assess the clinical utility of this assay are warranted.

AB - Purpose: This study was aimed at developing and validating a quantitative multigene assay for predicting tumor recurrence after gastric cancer surgery. Experimental Design: Gene expression data were generated from tumor tissues of patients who underwent surgery for gastric cancer (n = 267, training cohort). Genes whose expression was significantly associated with activation of YAP1 (a frequently activated oncogene in gastrointestinal cancer), 5-year recurrence-free survival, and 5-year overall survival were first identified as candidates for prognostic genes (156 genes, P < 0.001). We developed the recurrence risk score (RRS) by using quantitative RT-PCR to identify genes whose expression levels were significantly associated with YAP1 activation and patient survival in the training cohort. Results: We based the RRS assay on 6 genes, IGFBP4, SFRP4, SPOCK1, SULF1, THBS, and GADD45B, whose expression levels were significantly associated with YAP1 activation and prognosis in the training cohort. The RRS assay was further validated in an independent cohort of 317 patients. In multivariate analysis, the RRS was an independent predictor of recurrence [HR, 1.6; 95% confidence interval (CI), 1.02-2.4; P = 0.03]. In patients with stage II disease, the RRS had an HR of 2.9 (95% CI, 1.1-7.9; P = 0.03) and was the only significant independent predictor of recurrence. Conclusions: The RRS assay was a valid predictor of recurrence in the two cohorts of patients with gastric cancer. Independent prospective studies to assess the clinical utility of this assay are warranted.

UR - http://www.scopus.com/inward/record.url?scp=85006963551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006963551&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-2468

DO - 10.1158/1078-0432.CCR-15-2468

M3 - Article

C2 - 27654712

AN - SCOPUS:85006963551

VL - 22

SP - 6228

EP - 6235

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -